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Background and purpose: Patients with prostate cancer (PC) and a symptomatic pelvic tumor may be trea-
ted with palliative pelvic radiotherapy for symptom relief or to delay symptom progression. Radiotherapy
dose and fractionation regimens vary. We aimed to provide an overview of the literature and to evaluate
palliative pelvic radiotherapy of PC focusing on symptomatic effect, quality of life (QOL), and toxicity, and
to determine the optimal radiotherapy schedule. Material and methods: Systematic literature searches of
Medline, Embase and Cochrane databases were performed through 2011. Studies reporting symptom and
QOL responses were eligible. Results: Nine studies were included, all retrospective chart reviews. There
were large variations in radiotherapy dose and fractionation. Overall symptom response rate was 75%
and positive responses were reported for hemorrhage (73%), pain (80%), bladder outlet obstruction
(63%), rectal symptoms (78%) and ureteric obstruction (62%). Toxicity results were not evaluable. Conclu-
sions: Despite limitations in the review process and the included studies, we conclude that pelvic radio-
therapy for symptomatic PC appears to provide effective palliation of a variety of symptoms. There is
currently no valid documentation regarding onset or duration of palliation. No recommendations can
be provided regarding target dose or fractionation schedule in this context.
 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology
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narios where the cancer has spread beyond the prostate gland,
although there is controversy regarding the extraprostatic exten-
sion that rules out a curative treatment approach [1]. Advanced
prostate cancer commonly disseminates to the skeleton and lymph
nodes. Androgen deprivation is the most common initial therapeu-
tic approach in this situation although resistance to castrate levels
of testosterone typically develops after approximately 3 years of
treatment [2]. Among 15–20% of these cases of castration-resistant
prostate cancer (CRPC), the clinical picture is dominated by local
extension of the primary tumor [3] resulting in pelvic symptoms
such as pain, obstruction and hemorrhage. Palliative pelvic radio-
therapy may, in such cases, relieve existing symptoms, prevent
symptom progression and delay local extension.There is a movement toward hypofractionated, simpliﬁed
palliative radiotherapy regimens in several clinical scenarios that
have demonstrated equivalent symptomatic responses to those
achieved with traditional, longer courses of treatment [4,5]. No
standard regimen exists for the delivery of palliative pelvic radio-
therapy of prostate cancer. Approximately 50% of all radiotherapy
courses are given with palliative intent and this ﬁgure is predicted
to increase [6]. Palliative pelvic radiotherapy of prostate cancer re-
mains underutilized, likely as a consequence of the lack of good
evidence of its effect and fear of toxicity [7]. To the best of our
knowledge, there are no published reviews that summarize the
evidence of its palliative treatment effects.
The aim of this systematic review was to identify and evaluate
published studies describing the effects of palliative pelvic external
beam radiotherapy (EBRT) of symptomatic, incurable prostate can-
cer in order to determine its effect on pelvic symptoms and quality
of life (QOL). We also reviewed the toxicity reported in order to
gain a better understanding of the risk–beneﬁt balance. Further-
more, we attempted to evaluate treatment schedules in order to
determine whether there exists an optimal dose or fractionation
scheme. Implications of the ﬁndings for clinical practice and future
research are discussed.
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Within limitations imposed by the nature of the existing publi-
cations on palliative pelvic radiotherapy of prostate cancer, we
have followed the guidelines for a qualitative synthesis laid out
in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA statement [8]. In addition, the review
process followed a scientiﬁc research protocol.Search strategy
Searches of the Medline, Embase and Cochrane library dat-
abases were performed through December, 2011. The following
MESH terms illustrate the search strategy used in Medline: (radio-
therapy OR radiation OR radiation oncology) AND (palliative care or
terminal care) AND prostatic neoplasms. Resultant titles/abstracts
were screened by four authors (MC, MG, CK, IV). Further studies
were identiﬁed manually from the reference lists of articles re-
viewed in full-text (MC). Studies were identiﬁed by their English
title (used in database indexing and in reference lists). All studies
published in European languages were considered for inclusion.
Native speakers were used to assess eligibility and translations
were performed as necessary.Eligibility criteria
Published full-text studies that evaluated pelvic EBRT of pros-
tate cancer given with palliative intent were considered eligible
for inclusion. Studies that evaluated these patients as a subgroup
were also included, as long as results within this subgroup were
clearly reported. Reports evaluating curative radiotherapy doses
given in ‘‘palliative situations’’ were included if the incurable pa-
tients could be identiﬁed as a subgroup. Only studies that reported
symptom or QOL outcomes were included. All study designs (other
than case-reports and reviews) were eligible. Published reports
using weak scientiﬁc methodology (including retrospective re-
views of patient charts) were included in order to ensure as com-
plete an overview of the existing evidence as possible. Studies
that combined palliative pelvic radiotherapy with other tumor-di-
rected interventions (except ongoing hormonal manipulation) and
those that evaluated re-irradiation were excluded.Evaluation of studies
There is no standard reliable and validated tool for assessing the
‘‘quality’’ of observational and other nonrandomized studies [9].
Articles were therefore evaluated using an assessment form based
partly on recommendations from the Cochrane group [10] and
modiﬁed for our use after pilot-testing. Our evaluation criteria
qualitatively focused on the internal validity of the individual stud-
ies and included an assessment of the risk of bias at the study and
outcome levels. Potential articles were evaluated at the full-text le-
vel by four of the authors (MC, MG, CK, IV) and ﬁnal selection was
based on consensus.Data extraction and management
Data regarding the study characteristics and outcomes of inter-
est (symptom response, QOL, and toxicity) were extracted from the
included studies, into tables. Data extraction was performed inde-
pendently by two reviewers (MC, IV) and a third reviewer was con-
sulted to resolve discrepancies. The data extraction procedure was
ﬁrst pilot tested on ﬁve randomly selected studies and then mod-
iﬁed before implementation. A meta-analysis was not feasible due
to the heterogeneity of studies being reviewed. Data are instead
presented in table form, using explanatory headings. An attempthas been made to link the quality of the included studies to the
interpretation of their results.
Results
Study selection
After removal of duplicates, the database searches yielded 927
records. These titles/abstracts were screened, leaving 184 records
(both original research and review), which were then reviewed
in full text. The reference lists of the selected full-text records
yielded an additional 43 articles for full-text review. The list of
full-length articles was reﬁned, according to the inclusion/exclu-
sion criteria, to a short-list of 34 eligible studies which were eval-
uated according to the preset assessment form. Of these, nine
studies met the inclusion criteria and were included in the ﬁnal
analysis (Fig. 1).Study characteristics
The median number of relevant patients in the included studies
was 26 (range 11–119) with a pooled total of 315 patients. The
studies described treatments spanning a 46-year period, from
1961 to 2007. None of the studies were prospective. Where meth-
ods of data collection were reported, symptom-data had been ex-
tracted retrospectively from physicians’ clinical notes. There were
no reports of QOL or other patient-reported outcomes (PROs). No
studies used standardized scales for symptom evaluation. An over-
view of the characteristics of the nine included studies can be
found in Table 1.Patient characteristics and symptoms
The study populations were heterogeneous (Table 1). Four stud-
ies included patients with both CRPC and castration-sensitive dis-
ease [11–14]. The six studies that reported the metastatic status of
their population, reported a combination of patients with and
without distant metastases [11–13,15–17]. There was a range of
target symptoms among the studies (Table 2) and not uncom-
monly, there were constellations of symptoms in the same pa-
tients. The most commonly reported symptoms were related to
bladder outlet obstruction (BOO), hemorrhage and pain. In addi-
tion, rectal symptoms and ureteral obstruction were indications
for treatment. Some patients were treated primarily to obtain local
tumor control and prevent tumor progression and thus, symptom-
atic response was a secondary ﬁnding [14,16].Radiotherapy dose and fractionation
Radiotherapy method, dose, schedule, and target deﬁnitions
were heterogeneous and varied greatly not only between studies,
but also within studies. Reported fraction sizes varied across stud-
ies from <2 to 8 Gy and total doses ranged from 8 to 76 Gy (Table 1).
The most commonly used fraction sizes were in the range of 2–
3 Gy daily. Calculation of biologically effective doses was not pos-
sible due to inadequate description of the radiotherapy delivered
in several of the studies.Treatment response
The deﬁnition of response criteria varied between the studies
and responses were reported at variable time points after radio-
therapy. In most studies response was deﬁned as symptomatic re-
lief, graded retrospectively by a physician or researcher on a 2–4
point scale (Table 1). Response in ureteric obstruction was
determined radiographically. Reported overall response, without
Medline + Embase + Cochrane
969
927 tles and abstract screened
184 publicaons
227 full text publicaons screened
34 studies evaluated for eligibility
9 studies included in ﬁnal analysis
42 duplicates
743 irrelevant
43 from 
reference
lists
193 irrelevant 
or reviews
Exclusions (25):
15 – no symptoms/QOL
8 – relevant subgroup not idenﬁable
2 – combinaon of treatments
Fig. 1. Study selection ﬂow chart.
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viewed studies [12,13,15–18], with a pooled response rate of
75%. Details are presented in Table 2 and where individual symp-
tom response data could be extracted from the studies, these have
been pooled into symptom categories (Table 3).Durability of response
Median duration of symptomatic relief could not be determined
due to heterogeneous reporting. See Table 2 for details. Among theTable 1
Characteristics of studies of palliative pelvic radiotherapy of prostate cancer.
Author/
year
Study design and
treatment period
Patients
N Hormone
manipulation
status
Carlton
1972
[11]
Retrospective
NR
N = 225, RSN = 119 locally
advanced
Mixed
Din 2009
[12]
Retrospective
2003–2007
N = 58 locally advanced, with
pelvic symptoms. RSN = 35
evaluable
Mixed
Fosså
1987
[13]
Retrospective
1976–1985
N = 19 locally advanced, with
pelvic symptoms
CRPC
Furuya
1999
[14]
Retrospective
1986–1995
N = 38 locally advanced,
RSN = 11 treated with EBRT
CRPC
Green
1974
[15]
Retrospective
1967–1973
N = 11 locally advanced, with
rectal symptoms
Mixed
Hindson
2007
[16]
Retrospective
2002–2006
N = 35 locally advanced, with
pelvic symptoms
CRPC
Kraus
1972
[17]
Retrospective
1961–1970
N = 33 locally advanced RSN = 27
evaluable
Mixed
Kynaston
1990
[18]
Retrospective
1980–1988
N = 26 locally advanced, with
urinary symptoms
CRPC
Perez
1993
[19]
Retrospective
NR
N = 26 locally advanced, with
pelvic symptoms
CRPC
N, number of subjects in the study; RSN, number of subjects in the relevant subgroup; Nrange of symptoms reported, hematuria tended to be an early
responding symptom and in some cases it resolved during the
course of radiotherapy [14] or after delivery of a single large frac-
tion [19].Dose–response
The studies could not reliably demonstrate a dose–response ef-
fect. Furuya claimed that higher radiotherapy doses may produceRadiotherapy (dose range/
fraction size/treatment
period)
Relevant outcome Patient
follow-up
(months)
Metastatic
status
Mixed 40–45 Gy Symptom relief,
dichotomized
NR
Mixed 20 Gy/4 Gy daily Symptom relief at 4
mo, 4 point scale
Median 8.3
Mixed 40–56 Gy/2 Gy daily Symptom relief
for > 2 mo, 3 point
scale
NR
Mixed 50–66.6 Gy Symptom relief,
dichotomized
Mean 25.4
(range 7–64)
Mixed 16–76 Gy/8 Gy weekly Symptom relief, 3
point scale
NR
Mixed 30–70 Gy/2–3 Gy (9 days
per 2 wk)
Symptom relief at 6
mo, 4 point scale
Median 7.8
NR 22.5–66 Gy/2 Gy daily Symptom relief Mean 11
(range 1–48)
NR 35 Gy/2.33 Gy daily/3 wk
8–24 Gy/8 Gy/days 0–7–21
Symptom relief, 4
point scale
NR
NR 50–60 Gy Symptom relief NR
R, not reported; mo, month; wk, week; CRPC, castration-resistant prostate cancer.
Table 2
Symptomatic response to palliative pelvic radiotherapy of prostate cancer.
Author Radiotherapy
dose (Gy)
Symptomsa included in the reported
response
Responseb (overall in bold text, speciﬁc symptoms listed) Duration
Carlton
1972
[11]
40–45 BOO, ureteral obstruction, hematuria BOO 20/40 (50%); hematuria 7/7; hydronephrosis 8/11 (73%) NR
Din 2009
[12]
10–20
med 20
Hematuria, BOO, rectal symptoms, pain 31/35 Patients (89%) at 4 mo; BOO 13/24 (54%); hematuria 13/
31 (42%); pain 11/16 (69%); rectal obstruction 12/16 (75%)
44% symptom response at 7
mo
Fosså
1987
[15]
36–52
med 50
Pain, micturition problems, ureteral
obstruction, rectal obstruction
12/19 Patients (63%); micturition problems 4/7; pain 6/8;
rectal stenosis 1/3; ureteric stenosis 2/4
3–24 mo
Furuya
1999
[16]
50–66.6 Pain, hematuria 4/4 Patients No recurrence of symptoms
Green
1974
[13]
16–76
med 65
Pain, rectal obstruction, BOO,
hematuria, ureteral obstruction,
dysuria, hemorrhoids
10/11 Patients (91%); BOO 4/4; hematuria 2/3; pain 7/7; rectal
obstruction 5/6; ureteral obstruction 0/2; dysuria 0/1;
hemorrhoids 1/1
Median 10.5 mo (range 0–
30)
Hindson
2007
[17]
30–70
med 60
BOO, hematuria, rectal obstruction,
pain
21/35 Patients (60%); BOO 18/27 (67%); hematuria 5/8 ;pain 3/
4; rectal obstruction 6/7
No documented progression
during follow-up
Kraus
1972
[14]
22.5–66
mostly 40–50
BOO, hematuria, rectal symptoms,
ureteral obstruction, pain, edema
Hematuria 13/13 (100%); rectal symptoms 5/5; ureteral
obstruction 4/5
Mean BOO relief 10 mo
(range 4–23)
Kynaston
1990
[18]
8–35 BOO, hematuria BOO 15/17 (88%); hematuria 13/13 (100%) BOO relief 5–24 mo (50% at
11 mo) Hematuria relief
P4 mo
Perez
1993
[19]
50–60 BOO, hematuria, rectal symptoms, pain 82% of symptoms; BOO 6/8; hematuria 5/5; pain 5/5; ureteral
obstruction 2/4
NR
a Symptoms are listed according to reported frequencies.
b Responses are dichotomized (response versus no response). NR, not reported; NS, not speciﬁed other than as ‘‘symptoms’’; BOO, bladder outlet obstruction; med, median;
mo, month.
Table 3
Pooled symptomatic response rates according to authors’ own deﬁnitions, at variable
time points after palliative pelvic radiotherapy.
Symptoms Pooled results
Overall response (speciﬁc symptom not indicated)
[12,13,15–18]
78/104 = 75%
Hemorrhage [11–14,17–19] 58/80 = 73%
Pain [12,13,15,17,18] 32/40 = 80%
Bladder outlet obstruction [11–13,17–19] 76/120 = 63%
Rectal symptoms [12–15,17] 29/37 = 78%
Ureteric obstruction [11,13–15,18] 16/26 = 62%
58 Palliative pelvic radiotherapy of prostate cancer - a systematic reviewprolonged local control [16] while Hindson did not ﬁnd a dose–re-
sponse among his population [17].Toxicity
Six of the nine studies addressed the toxicity of the radiother-
apy [11–14,16,19]. The toxicities reported were mostly mild/mod-
erate. The ﬁndings are summarized in Table 4. The speciﬁc
toxicities reported included proctitis, diarrhea, tenesmus, pollakis-
uria, dysuria, hematuria, dermatitis, emesis, lethargy and worsen-
ing ureteral obstruction. None of the procedures for documenting
toxicity in the included studies were systematic. One study used
a validated grading scale to describe the degree of toxicity [19].Discussion
This systematic review of the literature demonstrates the lack
of documentation regarding relevant outcomes of palliative pelvic
EBRT of prostate cancer. Despite a broad and comprehensive liter-
ature search, we found no prospective studies that complied with
our eligibility criteria. The included studies indicated a positive
effect of palliative pelvic radiotherapy on hemorrhage, pain, BOO,rectal symptoms and ureteric obstruction as well as an overall
symptomatic response among patients. We found no conclusive
evidence for a relationship between dose or fractionation and the
palliative effects.
PROs are the preferred measures with which to assess the
effects of palliative interventions among cancer patients. There
was a complete absence of PROs, including QOL, in the reviewed
studies.
Prospective studies of palliative pelvic radiotherapy of prostate
cancer are difﬁcult to conduct. Important obstacles include multi-
plicity and progression of symptoms and confounding treatments,
particularly increasing doses of analgesia, during study follow-up.
In addition, many patients have short life expectancies, making
adherence to study protocols difﬁcult.
The above factors may in part explain why the identiﬁed
publications are characterized by mostly small retrospective stud-
ies. Patient characteristics and radiotherapy prescriptions vary
substantially, even within studies, and the source documentation
from which the retrospective data have been extracted often lacks
important information about study subjects and evaluated treat-
ments. In addition, many studies evaluate radiotherapy without
reporting likely confounders such as previous treatment, hormonal
manipulation and concomitant analgesic medication use. As such,
their relative contributions cannot accurately be determined. This
limits the reliability and generalizability of the results concerning
the effectiveness of palliative pelvic radiotherapy.
The pooled overall response rate of 75% appears promising
despite shortcomings in the methods used to evaluate symptoms.
It is noteworthy that the favorable response rates reﬂect highly
variable radiotherapy practices. A proportion of those treated for
hemorrhage achieved partial or complete relief at relatively low
radiotherapy doses (most often single fractions of 8 Gy), although
some patients did eventually require retreatment [12]. The dura-
bility of this response appeared to be substantial and there was
response to retreatment in cases of symptom recurrence during
Table 4
Toxicity reported in studies of palliative pelvic radiotherapy of prostate cancer.
Study Acute toxicity Late toxicity
Gastrointestinal Genitourinary Skin/connective tissue
Carlton [11] 1972 Milda 16/119
moderateb 2/119
Mild 18/119
moderate 2/119
NR NR
Din [12] 2009 Mild 6/47
moderate 4/47
NR
Fosså [15] 1987 NR NR NR NR
Furuya [16] 1999 Mild 3/11 Mild 2/11 NR NR
Green [13] 1974 NR 1/11 severec (72 Gy) NR 1/11 rectal sloughing at 6 mo (76 Gy)
Hindson [17] 2007 NR NR NR NR
Kraus [14] 1972 Mild 18/33 1/33 ﬁstula at 8 mo
Kynaston [19] 1990 WHO grade 1–2 None Mild None
Perez [18] 1993 NR NR NR NR
NR, not reported; mo, months; WHO, World Health Organization.
a Mild indicates that the author has described the toxicity as ‘‘mild’’ or as not requiring more than symptomatic measures.
b Moderate indicates that the author has described the toxicity as ‘‘moderate’’ or that the treatment was interrupted due to toxicity.
c Severe indicates that the author has described the toxicity as ‘‘severe’’ or that the treatment was discontinued due to toxicity.
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ies of hypofractionated radiotherapy of bone metastases [5]. Both
patients with pain and with obstructive symptoms, including
BOO and rectal disturbance appear to have been palliated and
whereas it is unclear to what degree analgesics were used, the
duration of responses approached one year in several of the re-
viewed studies [13,14,19].
The frequency of complications and degree of toxicity are most
likely underestimated in the included studies due to the non-sys-
tematic manner in which the patients were followed up. In addi-
tion, late toxicity and local disease progression may be difﬁcult
to differentiate, as exempliﬁed by ﬁstula-formation eight months
after radiotherapy in the study by Kraus et al. [14]. In studies of
palliative interventions, carefully weighing the burden of treat-
ment against the beneﬁt provided is of utmost importance. In this
context, patient reported toxicity should be assessed in a prospec-
tive and systematic manner using validated instruments.
Several studies reported highly variable radiotherapy prescrip-
tions, with total doses that varied up to nearly ﬁvefold [13].
Although all nine studies reported symptomatic improvement in
the majority of patients, they did not allow for conclusions regard-
ing dose–response or the most effective fractionation regimens.
While Furuya described a relationship between dose and survival
among his sample, this trend should be interpreted with caution
as it may be the result of selection of patients with longer
life-expectancies for more intensive treatments rather than dem-
onstration of a life-prolonging effect of the palliative radiotherapy
itself. The studies do not document that palliative radiotherapy of
the pelvic tumor improves survival time among patients with met-
astatic disease. However, patients with incurable prostate cancer
conﬁned to the pelvis seem to have better prognoses compared
to those with systemic disease [16,20]. This is an important consid-
eration when selecting patients for higher target doses of palliative
pelvic radiotherapy where there is hope for prolonged survival and
subsequent need for prolonged pelvic tumor control. However, if
symptomatic effect can be shown with hypofractionated radio-
therapy or at low total doses, more patients are likely to be referred
for this treatment in the future.
There are risks of bias intrinsic to the review process that
should be taken into consideration when interpreting these results.
In particular, negative studies and those without signiﬁcant ﬁnd-
ings systematically remain unpublished which may lead to overes-
timation of the effect of a speciﬁc intervention. Retrospective
extraction of physician reported symptom response presents a risk
of bias, potentially leading to an overly optimistic result of the
treatment effect [21]. Attrition may also introduce bias as theincluded patients have relatively short life expectancies and many
were lost to follow-up [12]. In addition, it may be inappropriate to
extrapolate some aspects of the older studies to today’s clinical
scenarios as staging procedures and radiotherapy techniques have
changed considerably during the last 20 years.
Conclusion
Palliative pelvic radiotherapy of prostate cancer appears effec-
tive for a range of symptoms, with a favorable beneﬁt to toxicity
ratio. However, based on the current literature, it is impossible to
draw reliable conclusions regarding the magnitude, onset or dura-
tion of the beneﬁcial and detrimental effects. In addition, optimal
dose and fractionation regimen still need to be deﬁned. A better
understanding of these unresolved issues must come from pro-
spective studies of patient-reported symptom response and QOL
[22].
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